Watching Denali Therapeutics Inc.? See every signal: funding, hires, M&A, contracts, sentiment.
Book a demoChoose your planDenali Therapeutics Inc.
AI Executive Summary
AI-powered analysis of 8-K filing content
Denali Therapeutics completed the sale of its Rare Pediatric Disease Priority Review Voucher (PRV) for $195 million on July 27, 2026, following FDA approval of AVLAYAH for Hunter syndrome. This strategic divestiture provides substantial capital for reinvestment in R&D initiatives.
Key Takeaways
Denali received $195.0 million in gross proceeds from the sale of its PRV to a large pharmaceutical company
The PRV was obtained following FDA approval of AVLAYAH (tividenofusp alfa) for Hunter syndrome in March 2026
2 more takeaways
Filing Overview
What This Means
Denali Therapeutics Inc. filed with the SEC. Fundz turns 8-K material events into an alert with the right executive attached.
145 of these a day, filtered to the companies you pick. $29 a month, billed annually, and if it does not pay for itself in a year we refund it.